These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 29962197)

  • 1. [Construction and Immunogenicity Analysis of Herpes Simplex Virus Type 2 Glycoprotein D Recombinant Adenovirus Vaccine].
    Liu W; Zhao D; Wang Z; Li Y; Wang H; Wang H
    Bing Du Xue Bao; 2016 May; 32(3):267-72. PubMed ID: 29962197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
    Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
    J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs.
    Bernard MC; Barban V; Pradezynski F; de Montfort A; Ryall R; Caillet C; Londono-Hayes P
    PLoS One; 2015; 10(4):e0121518. PubMed ID: 25837802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of recombinant adenovirus vaccines based on glycoprotein D and truncated UL25 against herpes simplex virus type 2 in mice.
    Liu W; Zhou Y; Wang Z; Zhang Z; Wang Q; Su W; Chen Y; Zhang Y; Gao F; Jiang C; Kong W
    Microbiol Immunol; 2017 May; 61(5):176-184. PubMed ID: 28378925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.
    Awasthi S; Huang J; Shaw C; Friedman HM
    J Virol; 2014 Aug; 88(15):8421-32. PubMed ID: 24829358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine.
    Awasthi S; Belshe RB; Friedman HM
    J Infect Dis; 2014 Aug; 210(4):571-5. PubMed ID: 24652496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection.
    Shlapobersky M; Marshak JO; Dong L; Huang ML; Wei Q; Chu A; Rolland A; Sullivan S; Koelle DM
    J Gen Virol; 2012 Jun; 93(Pt 6):1305-1315. PubMed ID: 22398318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the herpes simplex virus type 2 glycoprotein D in baculovirus expression system and evaluation of its immunogenicity in guinea pigs.
    Fotouhi F; Soleimanjahi H; Roostaee MH; Dalimi Asl A
    Iran Biomed J; 2008 Apr; 12(2):59-66. PubMed ID: 18506211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of DNA immunization formulated with bupivacaine in murine and guinea pig models of genital herpes simplex virus infection.
    Bernstein DI; Tepe ER; Mester JC; Arnold RL; Stanberry LR; Higgins T
    Vaccine; 1999 Apr; 17(15-16):1964-9. PubMed ID: 10217595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a glycoprotein D-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in mice.
    Akhrameyeva NV; Zhang P; Sugiyama N; Behar SM; Yao F
    J Virol; 2011 May; 85(10):5036-47. PubMed ID: 21389121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient production of recombinant glycoprotein D of herpes simplex virus type 2 in Pichia pastoris and its protective efficacy against viral challenge in mice.
    Wang M; Jiang S; Zhou L; Wang C; Mao R; Ponnusamy M
    Arch Virol; 2017 Mar; 162(3):701-711. PubMed ID: 27868164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs.
    Heineman TC; Connelly BL; Bourne N; Stanberry LR; Cohen J
    J Virol; 1995 Dec; 69(12):8109-13. PubMed ID: 7494331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs.
    Hoshino Y; Dalai SK; Wang K; Pesnicak L; Lau TY; Knipe DM; Cohen JI; Straus SE
    J Virol; 2005 Jan; 79(1):410-8. PubMed ID: 15596834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of protective humoral (Th2) and cell-mediated (Th1) immune responses against herpes simplex virus-2 through co-delivery of granulocyte-macrophage colony-stimulating factor expression cassettes.
    Sin JI; Kim JJ; Ugen KE; Ciccarelli RB; Higgins TJ; Weiner DB
    Eur J Immunol; 1998 Nov; 28(11):3530-40. PubMed ID: 9842896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Adenovirus-Based Recombinant Herpes Simplex Virus 2 (HSV-2) Therapeutic Vaccine Is Highly Protective against Acute and Recurrent HSV-2 Disease in a Guinea Pig Model.
    Wan M; Yang X; Sun J; Ding X; Chen Z; Su W; Cai L; Hou A; Sun B; Gao F; Jiang C; Zhou Y
    Viruses; 2023 Jan; 15(1):. PubMed ID: 36680259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with HSV-2 gB-CCL19 Fusion Constructs Protects Mice against Lethal Vaginal Challenge.
    Yan Y; Hu K; Deng X; Guan X; Luo S; Tong L; Du T; Fu M; Zhang M; Liu Y; Hu Q
    J Immunol; 2015 Jul; 195(1):329-38. PubMed ID: 25994965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine-induced antibodies to herpes simplex virus glycoprotein D epitopes involved in virus entry and cell-to-cell spread correlate with protection against genital disease in guinea pigs.
    Hook LM; Cairns TM; Awasthi S; Brooks BD; Ditto NT; Eisenberg RJ; Cohen GH; Friedman HM
    PLoS Pathog; 2018 May; 14(5):e1007095. PubMed ID: 29791513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone.
    Meseda CA; Elkins KL; Merchlinsky MJ; Weir JP
    J Infect Dis; 2002 Oct; 186(8):1065-73. PubMed ID: 12355355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of intramuscular and footpad subcutaneous immunization with DNA vaccine encoding HSV-gD2 in mice.
    Jazayeri M; Soleimanjahi H; Fotouhi F; Pakravan N
    Comp Immunol Microbiol Infect Dis; 2009 Sep; 32(5):453-61. PubMed ID: 18571235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs.
    Hoshino Y; Pesnicak L; Dowdell KC; Burbelo PD; Knipe DM; Straus SE; Cohen JI
    J Infect Dis; 2009 Oct; 200(7):1088-95. PubMed ID: 19702506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.